Pure Global AI
NCT05873400Recruiting

Effect of Renin Angiotensin Aldosterone System Genetic Polymorphism on the Pharmacological Effect of Mineralocorticoid Receptor Antagonists in Patients With Myocardial Infarction

Ain Shams UniversityClinicalTrials.gov
Verified
Study focus
Disease/Condition
Myocardial Infarction
Study type
Observational
Sponsor & location
Primary sponsor
Ain Shams University
Location
Cairo, Egypt
Timeline & enrollment
Phase
N/A
Start date
Aug 01, 2022
End date
Apr 01, 2024
Enrollment
102 participants
Primary outcome

Genetic polymorphism

Summary

Early treatment of Myocardial Infarction patients with mineralocorticoid receptor antagonist
 with help reduces the incidence of cardiac remodeling and development into heart failure.
 Also studying aldosterone synthase (CYP11B2) and mineralocorticoid receptor (NR3C2) gene
 polymorphisms in Egyptian Myocardial Infarction patients will help tailor medication therapy
 and optimize therapeutic effects with the least adverse effects.

ICD-10 classifications
Acute myocardial infarctionAcute myocardial infarction, unspecifiedOld myocardial infarctionSubsequent myocardial infarctionObservation for suspected myocardial infarction
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05873400
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05873400 through Pure Global AI's free database. This phase not specified trial is sponsored by Ain Shams University and is currently Recruiting. The study focuses on Myocardial Infarction. Target enrollment is 102 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.